HC Wainwright set a $33.00 price target on RedHill Biopharma Ltd. (NASDAQ:RDHL) in a research note released on Friday. The brokerage currently has a a buy rating on the stock.
RDHL has been the topic of a number of other reports. Zacks Investment Research upgraded shares of RedHill Biopharma from a sell rating to a hold rating in a research note on Friday, August 26th. FBR & Co lifted their price objective on shares of RedHill Biopharma from $33.00 to $36.00 and gave the company an outperform rating in a research note on Wednesday, July 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) opened at 14.2709 on Friday. The firm has a 50-day moving average of $14.60 and a 200 day moving average of $12.82. The stock’s market capitalization is $181.73 million. RedHill Biopharma has a 12-month low of $8.10 and a 12-month high of $16.54.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.52. Equities analysts forecast that RedHill Biopharma will post ($2.06) earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of RDHL. Van ECK Associates Corp increased its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of RedHill Biopharma during the second quarter valued at $142,000. Royal Bank of Canada increased its stake in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in shares of RedHill Biopharma during the second quarter valued at $451,000. 15.30% of the stock is currently owned by institutional investors and hedge funds.
About RedHill Biopharma